|1.||Yamada, T: 3 articles (04/2001 - 10/2000)|
|2.||Aoki, M: 3 articles (04/2001 - 10/2000)|
|3.||Kobayashi, M: 2 articles (04/2001 - 10/2000)|
|4.||Miyata, K: 2 articles (04/2001 - 10/2000)|
|5.||Cox, Gerard: 1 article (08/2012)|
|6.||Dolovich, Myrna B: 1 article (08/2012)|
|7.||Yaghi, Asma: 1 article (08/2012)|
|8.||Zaman, Aisha: 1 article (08/2012)|
|9.||Mitsui, Takahiko: 1 article (11/2008)|
|10.||Kitta, Takeya: 1 article (11/2008)|
12/01/2000 - "We compared the anti-inflammatory activity of YM976 with its emetic activity in ferrets, in which it dose dependently suppressed eosinophil infiltration at an ED(50) value of 1.2 mg/kg, but induced no emesis at 10 mg/kg. This suggested that the compound exhibits a considerable dissociation between its anti-inflammatory and emetic effects. "
10/01/2000 - "YM976 produced no emesis up to 10 mg/kg, whereas rolipram and RP73401 induced emesis at oral doses of 3 mg/kg. To evidence the dissociation of anti-inflammatory activity from emesis, the anti-inflammatory effect of YM976 was examined in ferrets. "
07/10/2006 - "In contrast to YM976, YM-393059 did not shorten the duration of alpha2-adrenoceptor agonist-induced sleep in mice, which is a model for the assessment of the typical side effects caused by PDE4 inhibitors, nausea and emesis. "
|3.||Asthma (Bronchial Asthma)
|4.||Chronic Obstructive Pulmonary Disease (COPD)
08/01/2012 - "There was an evident and persistent rise in CBF with all agents tested in COPD cilia except that YM976 effects persisted only in severe COPD. "
08/01/2012 - "Then, CBF was re-measured after 30 min perfusion with pharmacologic agents that modulate mediators implicated in COPD (salmeterol xinafoate, tiotropium bromide, licofelone, luteolin, YM976, Defensin HNP-1) and again after 30 min washout. "
11/01/2008 - "To evaluate the effects of orally administered YM976, a specific inhibitor of type 4 phosphodiesterase (PDE4), on bladder activity in a rat model with hydrochloric acid (HCl)-induced cystitis (IC), hypothesizing that a PDE4 inhibitor might suppress bladder overactivity and bladder pain responses in bladder-hypersensitive disorders such as IC. "
|2.||Phosphodiesterase 4 Inhibitors
|4.||Hydrochloric Acid (Hydrogen Chloride)
|5.||Dihydrotachysterol (AT 10)
|6.||N- (4,6- dimethylpyrimidin- 2- yl)- 4- (2- (4- methoxy- 3- methylphenyl)- 5- (4- methylpiperazin- 1- yl)- 4,5,6,7- tetrahydro- 1H- indol- 1- yl)benzenesulfonamide difumarate